Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.

Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.

View in: PubMed